Log In

 

Company Name : Ferring Pharmaceuticals

Thursday, February 15, 2018 4:13PM IST (10:43AM GMT)

(BW)(FERRING-PHARMACEUTICALS)

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland


Ferring expands its capabilities in biologics through a new biotech centre, which will be installed at its global headquarters and manufacturing site in St Prex, Switzerland; Ferring Biotech Centre will incorporate discovery and development capabilities for monoclonal antibodies as well as manufacturing capabilities for biologics; In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centre


Saint-Prex, Switzerland

Ferring Pharmaceuticals announced that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.

 

Over the next three years, Ferring will invest approximately 30 million CHF in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.

 

“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas, and will open up additional opportunities for Ferring to help people live better lives.”

 

In addition to the discovery, development and manufacture of new biologics, the active pharmaceutical ingredient (API) for Rekovelle® (follitropin delta), Ferring’s latest fertility treatment, will also be manufactured at the new Ferring Biotech Centre.

 

Earlier this year, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics to create innovative solutions for patients.

 

- Ends -

 

About Ferring Pharmaceuticals:

 

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

 

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com


More News from Ferring Pharmaceuticals

29/05/2018 5:50PM

Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting

It is likely to be hereditary: children whose parents wet the bed are more likely to be bedwetters1 The world’s first genome-wide association study (GWAS) in bedwetting identify specific genetic variants that ...

05/05/2018 12:43PM

Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients

Ferring Pharmaceuticals announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being ...

06/04/2018 2:53PM

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human ...

Similar News

19/06/2018 1:18PM

Healthhunt Now Widens Its Reach to 200 Million People by Launching in Hindi

Healthhunt, a leading and highly-engaging online platform in the health and wellness space in Asia, today announced the mirror-image of their English website healthhunt.in in Hindi.

No Image

19/06/2018 11:17AM

LG Chem Hosts Global Innovation Contest 2018 (GIC 2018) "Finding Innovations to Change the World"

- Proposal submission from June 18th to September 30th - Applicants can register through the official website of GIC - Energy, Environment, Functional Materials, and Biotechnology are the subjects of the contest - ...